The story began in 1994 when the Multidisciplinary Association for Psychedelic Studies (MAPS) introduced Dr. Kolp to Dr. Evgeny Krupitsky, a Soviet researcher specializing in ketamine psychotherapy. Inspired by the scientific work of Dr. Krupitsky, who conducted the most comprehensive and rigorous clinical research on ketamine-assisted psychotherapy to date, Dr. Kolp first discovered the potential of ketamine as an adjunct to psychotherapy in 1994. In 1995, he developed a research protocol, entitled Ketamine-Assisted Therapy of Alcoholism. The protocol was reviewed and approved by the James A. Haley Veterans Hospital , the University of South Florida College of Medicine , and the U.S. Food and Drug Administration (FDA) . After receiving an Investigational New Drug permit in 1996, Dr. Kolp became engaged in research into the effectiveness of ketamine-assisted therapy for the treatment of alcoholism.
After collecting preliminary data and gaining experience administering ketamine-assisted therapy, Dr. Kolp began using ketamine-assisted psychotherapy for clinical applications in his private practice. In 2003, he founded the not-for-profit foundation Eleusis to utilize what he called “ketamine-enhanced psychotherapy” (KEP) to treat his alcoholic clients. His approach was explicitly designed to replicate Krupitsky’s pioneering work and apply it in a new cultural context: the United States. Like Krupitsky’s technique, Dr. Kolp’s KEP relies on a ketamine-induced transpersonal experience to facilitate psychotherapeutic changes.
In addition to KEP, the Wellness Enhancement and Longevity Learning (WELL) Program at Eleusis incorporated existential and transpersonal group psychotherapies, as well as several various alternative therapeutic techniques including meditation, guided imagery, visualization, Holotropic Breathwork, yoga, and Wisdom Circle groups. The three-week WELL program offered more than 90 hours of encounter groups, interactive classes, and didactic lectures in a structured residential setting.
During the same period of time, Dr. Kolp administered KEP for people suffering from death anxiety during the end stage of terminal cancer. Dr. Kolp offered KEP to hospice clients to help them resolve their fears when confronting death. KEP, combined with existential and transpersonal psychotherapy, was administered to dying patients as part of an intensive, individual outpatient treatment consisting of five 75 to 80-minute sessions.
Dr. Kolp found that two-thirds of his alcoholic patients responded well to KEP, and many recovered from their addiction. Many of his patients also showed significant or moderate improvement in their co-existing psychological and psychosomatic illnesses, such as generalized anxiety disorder, social phobias, primary insomnia, acute and repeated stress disorder, pain disorder, tension and migraine headaches, somatization disorder, and chronic fatigue syndrome.
Dr. Kolp now offers two dynamic, outpatient treatment protocols, Ketamine Pharmaco-therapy and Ketamine Enhanced Psychotherapy, for patients suffering from treatment-resistant depression and severe anxiety.